Clinical Features of Rapidly Progressive Alzheimer's Disease by Schmidt, Christian et al.
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Original Research Article 
 Dement Geriatr Cogn Disord 2010;29:371–378 
 DOI: 10.1159/000278692 
 Clinical Features of Rapidly Progressive 
Alzheimer’s Disease 
 Christian Schmidt  a    Katharina Redyk  a    Bettina Meissner  a    Lennart Krack  a    
Nico von Ahsen  b    Sigrun Roeber  c    Hans Kretzschmar  c    Inga Zerr  a 
 Departments of  a   Neurology and  b   Clinical Chemistry, Hospital of the Georg August University Goettingen, 
 Goettingen , and  c   Department of Neuropathology, Hospital of the Ludwig Maximilian University Munich,  Munich , 
Germany 
 Introduction and Objectives 
 Alzheimer’s disease (AD) is the most frequent cause of 
dementia  [1] . In most cases, the progression of the disease 
is slow with a disease duration of approximately 10 years 
while rapid progression is observed in some cases  [2–4] . 
Rapid progression can be defined by decline on psycho-
metric tests such as the Mini Mental State Examination 
score, e.g. 5 points/year  [3] , or on a basis of survival time, 
e.g. less than 4 years  [5] . At the moment no consensus on 
the term ‘rapidly progressive dementia’ exists. A need for 
a definition therefore becomes obvious and a discussion 
on that topic should be encouraged. Several patients with 
rapidly progressive dementia (very fast cognitive decline) 
and additional focal neurological symptoms consistent 
with prion disease such as Creutzfeldt-Jakob disease 
(CJD) often featuring a notably short time of survival 
were reported to the German National Surveillance Unit 
for Transmissible Spongiform Encephalopathies (TSE). 
As was discovered post mortem, these patients had actu-
ally been suffering from AD as the most frequent differ-
ential diagnosis  [6–11] . Since these patients might repre-
sent a peculiar subgroup of AD patients, we performed a 
study with respect to clinical and genetic characteristics 
as well as cerebrospinal fluid (CSF) biomarkers.
 Limited data are available on the frequency of focal neu-
rological signs in AD. Rapidly progressive AD forms have 
been described, and early occurrence of focal signs was re-
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 Abstract 
 Objective: To characterize clinical features, CSF biomarkers 
and genetic polymorphisms of patients suffering from a rap-
idly progressing subtype of Alzheimer’s dementia (rpAD). 
 Methods: Retrospective analyses of 32 neuropathologically 
confirmed cases differentially diagnosed as AD out of a 
group with rapidly progressive dementia. CSF biomarkers 
(14-3-3, tau,   -amyloid 1–42) and genetic markers ( PRNP co-
don 129, apolipoprotein E, ApoE, polymorphism) were deter-
mined.  Results: Median survival was 26 months, age at onset 
73 years. Biomarkers: mean   -amyloid 1–42: 266 pg/ml, me-
dian tau: 491 pg/ml, 14-3-3 positive: 31%. Genetic polymor-
phisms showed a predominance of methionine homozygos-
ity at  PRNP codon 129 and a low frequency of ApoE4 (38%, 
no homozygous patients). Thirty-five symptoms were stud-
ied. Frequent symptoms were myoclonus (75%), disturbed 
gait (66%) and rigidity (50%).  Discussion: rpAD is associated 
with a diversity of neurological signs even able to mimic 
Creutz feldt-Jakob disease. Biomarkers and genetic profile 
differ from those seen in classical AD. The findings on bio-
markers, symptomatology and genetics may aid the differ-
ential diagnostic process.  Copyright © 2010 S. Karger AG, Basel 
 Accepted: January 19, 2010 
 Published online: May 5, 2010 
 Dr. Christian Schmidt 
 Department of Neurology, Georg August University of Goettingen 
 Robert-Koch-Strasse 40,  DE–37075 Goettingen (Germany) 
 Tel. +49 55 139 6636, Fax +49 55 139 7020
E-Mail christian.schmidt   @   medizin.uni-goettingen.de 
 © 2010 S. Karger AG, Basel
1420–8008/10/0294–0371$26.00/0 
 Accessible online at:
www.karger.com/dem 
 Schmidt  /Redyk  /Meissner  /Krack  /
von Ahsen  /Roeber  /Kretzschmar  /Zerr  
Dement Geriatr Cogn Disord 2010;29:371–378 372
ported to indicate poor prognosis  [12, 13] . Our aim was to 
characterize the clinical features of our patients giving a 
descriptive overview of this highly selected group with 
rapidly progessing AD (rpAD). Considering contradictory 
data on genetic polymorphisms such as prion protein gene 
 (PRNP) codon 129 or apolipoprotein (Apo) E type and the 
rate of AD progression  [14–16] , it was also an objective to 
determine these genetic markers in the rpAD group.
 Methods 
 Patients who met the inclusion criteria as follow were included 
into the study:
 1 having been reported to the German National CJD Surveil-
lance Unit because of clinically suspected prion disease;  
 2 having been reported within a time period from 1993 to 2004; 
 3 post mortem neuropathological examination available; 
 4 neuropathological examination having revealed sufficient ev-
idence of AD pathology while excluding prion disease as well 
as other relevant neurological disorders (e.g. significant brain 
infarction). 
 The number of patients selected was 32 ( table 1 ). All patients 
had been examined by a study physician at the notifying hospital. 
Informed consent to participate in a study striving to monitor 
CJD epidemiology in Germany as well as to advance differential 
diagnostics of rapid dementias had been obtained. None of the 
patients had suffered from severe psychiatric or neurological dis-
eases prior to the onset of the rapid dementia. CSF and blood 
samples had been taken, as well as copies of relevant diagnostic 
test results (MRI, EEG, laboratory tests) shortly after patients had 
been reported to the Surveillance Unit. A questionnaire concern-
ing the patient’s history had been filled out. 
 Clinical characteristics being the presence of 35 distinct neu-
rological, psychiatric and autonomic symptoms as well as their 
time of occurrence were examined. Analysis of the symptoms’ me-
dian time span from clinical onset of the disease to the disease’s 
fatal end point was performed. The time point of the clinical onset 
was determined by means of semistructured interviews with fam-
ily members, the treating physicians and persons having had regu-
lar contact with the patient. The disease duration was then divided 
into thirds. The proportions of the rpAD study population devel-
oping symptoms in one of these three thirds of the disease dura-
tion were evaluated, thereby gaining insight into whether a symp-
tom emerged in an early, middle or late stage (‘clinical profile’). 
 If available, CSF parameters were examined. These included the 
proteins 14-3-3, tau and   -amyloid 1–42. Hyperphosphorylated 
tau protein and   -amyloid 1–40 had to be excluded because, due to 
the retrospective study design comprising cases from the years 
1993 until 2004, these biomarkers had not been determined regu-
larly. Therefore depiction of phosphorylated tau and   -amyloid 
1–40 mean values of a group too small was not considered mean-
ingful. Protein 14-3-3 analysis had been performed at least twice in 
each CSF sample as described previously  [17] . Tau protein had been 
measured by Innotest hTau ELISA, and   -amyloid 1–42 by In-
notest   -amyloid 1–42 ELISA (Innogenetics N.V., Ghent, Belgium). 
 Genetic features determined comprised ApoE and  PRNP gene 
codon 129 polymorphisms. Analysis had been carried out by 
means of standard methods  [18] . The prevalence of clinical signs 
stratified by  PRNP codon 129 genotype was analyzed subsequent-
ly and compared by means of Fisher’s exact test.
 Results 
 The median disease duration (clinical onset to death) 
was 26.4 months, and the median age at clinical onset 73 
years ( table 1 ). The gender proportion appeared to be bal-
anced almost equally. No significant difference in sur-
vival or age at onset could be seen when comparing pa-
tients being methionine-homozygous with non-methio-
nine-homozygous patients at  PRNP codon 129. 
 Pathological changes suggestive of proteinase-K-resis-
tant or proteinase-K-sensitive  [19] prion disease was ab-
sent while evidence of AD was seen in all cases. Retro-
spectively reviewing the results of the neuropathological 
examination, standard Braak and CERAD classification 
was performed in 28 cases, while 4 had not been available 
to our access. In the nonclassified cases, the pathological 
diagnosis was ‘Alzheimer’s dementia’. Of those classified, 
Braak and CERAD stages were distributed as given in 
 table 1 . Negligible Lewy body pathology could be found 
in 2 of the 32 cases, a meningioma in 1 case (right parietal 
convexity, diameter: 1.5 cm) and a subependymoma (9  ! 
4  ! 5 mm frontal cornu of the left lateral ventricle) in 
another case, the latter two probably not being the cause 
of dementia or death. Diffuse white-matter lesions of vas-
cular origin as expected considering the patients’ age 
were commonly seen. Other significant pathology, e.g. 
infarction, inflammatory disease, hemorrhage or rele-
vant tumor, was not present. 
 CSF tau values were determined in 29 patients with a 
median of 491 pg/ml ( table 1 ).   -Amyloid 1–42 levels had 
been analyzed in the CSF of 18 patients resulting in a 
mean level of 266 pg/ml ( table 1 ). Thirty-one percent of 
the entire rpAD study population (n = 32) were positive 
for CSF proteins 14-3-3 ( table 1 ).  PRNP gene codon 129 
polymorphism (M = methionine, V = valine) was evalu-
ated in 21 patients: 57% being homozygous for methio-
nine (M/M), 29% being heterozygous (M/V) and 14% 
possessing 2 valine alleles (V/V) as is depicted in  figure 
1 . Mutations were ruled out by sequencing of the entire 
 PRNP gene as previously reported  [18] . The ApoE status 
was studied in 16 patients revealing that no subject was 
homozygous for the type 4 allele (E4/E4), 6% possessed 
an E2/E4 combination, 31% were E3/E4 heterozygous, 6% 
were heterozygous for E2/E3, and E3/E3 homozygosity 
was seen in 56% ( fig. 2 ).
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 The detailed clinical profile is given in  figure 3 . The 
most frequent signs were myoclonus (75%), gait distur-
bance (66%), positive Babinski’s sign (66%), rigidity 
(50%), aphasia (66%), falls (50%) and hallucinations 
(44%). The least frequent symptoms were intention trem-
or (16%), disturbed vision (13%) and disinhibition (3%). 
Especially aphasia, myoclonus and rigidity were symp-
toms predominantly appearing in advanced disease stag-
es, while depression, disturbed gait and impaired concen-
tration occurred rather early in the disease course ( fig. 3 ). 
 Table 1. Properties of the rpAD study group including biomarkers
Category Value n
Median age at onset, years 73 (32, 60, 78, 89) 32
Median survival time, months 26.4 (1.3, 7.2, 45.4, 127.6) 32
Gender proportion (m:f), % 47:53 32
Clinical classification (CJD) probable: 16%, possible: 40%, left unclassified or ‘no CJD’: 44% 32
MRI (CJD) typical of CJD: 0, not typical: 53%, no MRI available: 47% 32
EEG (CJD) typical of CJD: 6%, not typical: 81%, no EEG available: 13% 32
Median CSF tau, pg/ml 491 (207, 323, 911, 4,736) 29
Mean CSF -amyloid 1–42 8 SD, pg/ml 2668120 18
CSF 14-3-3 protein positive, % 31 29
Neuropathology Braak stage, % III: 7, IV: 21, V: 39, VI: 32 28
Neuropathology CERAD stage, % A: 8, B: 15, C: 77 26
Figures in parentheses indicate 1st, 25th, 75th and 100th percentiles. Clinical classification from Zerr and Poser [11], MRI from 
Zerr et al. [48] and EEG from Zerr and Poser [11].
a b
c
M/M
M/V
V/V
57%
14%
29%
48%
11%
41%
40%
13%
47%
38%
63%
a b
59%
26%
15%
c
26%
72%
2%
ApoE4/E4
At least 1 ApoE4 allele
No ApoE4 allele
 Fig. 1. Distribution of the codon 129  (PRNP) polymorphism in the 
rpAD study population ( a , n = 21), a typical AD population ( b ,
n = 482, modified from Riemenschneider et al.  [32] ) and healthy 
controls ( c , n = 189, modified from Riemenschneider et al.  [32] ).  
 Fig. 2. Distribution of ApoE4 in the rpAD study population ( a ,
n = 16), a typical AD population ( b , modified from Farrer et al. 
 [37] ) and healthy controls ( c , modified from Farrer et al.  [37] ).  
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Category Sign/symptom Frequency
(total), %
Clinical profile:
symptoms' relative frequency within disease thirds
Median time
to symptom
onset, months
Early (1st third): black
Middle stage (2nd third): dark gray
Late stage (3rd third): light gray
Cerebellar
Extrapyramidal
Neurological (other)
Psychiatric
Autonomic
ataxia 31 12.5
dys/bradydiadochokinesia
dysmetria
dysarthria
intention tremor
rigidity
tremor
myoclonus
Babinski's sign
disturbed gait
aphasia
recurrent falls
hallucinations
akinetic mutism
primitive reflexes
apraxia
spasticity
epileptic seizures
palsies
dysphagia
diplopia
cortically disturbed vision
dementia
disorientation
depression
apathy
impaired concentration
anxiety
aggression
delusion/paranoia
disinhibition
incontinence
disturbed sleep
significant weight loss
hyperhidrosis
25
22
22
16
50
38
75
66
66
66
50
44
38
34
31
25
25
22
19
13
13
100
88
47
38
31
28
28
9
3
44
41
28
16
15.0
12.9
4.0
12.0
13.1
9.0
13.0
13.1
9.0
14.0
6.1
13.0
20.0
14.0
19.5
31.1
13.0
10.0
21.6
2.5
17.0
0.0
2.0
4.0
17.5
4.5
6.0
12.0
15.0
51.1
11.5
16.0
20.0
13.1
 Fig. 3. Clinical profile of the rpAD study group (n = 32). Frequency of signs and symptoms, total frequency, relative 
frequency (conditioned for disease thirds ‘early, middle, late’) and median time to symptom onset. 
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Differences in occurrence of clinical signs dependent on 
 PRNP codon 129 polymorphism were seen e.g. for hallu-
cinations, disturbed sleep and apraxia which were found 
to be especially frequent in M/M individuals. Epileptic 
seizures, primitive reflexes and akinetic mutism were 
particularly frequent in non-M/M individuals. Those 
differences were statistically significant for hallucina-
tions and epileptic fits.
 Discussion 
 As AD is a major challenge for the ageing society, it is 
of importance to advance the understanding of the un-
derlying mechanisms. Identification of different AD sub-
types using combinations of symptom patterns as well as 
biomarker constellations might have implications for de-
veloping appropriate management strategies. Typically, 
AD is a slowly progressive disease of the elderly. As Gold-
berg  [20] states, the time from clinical onset to diagnosis 
is about 24 months; thenceforward, the time until admis-
sion to a nursing home is about 25 months, and after that 
the modal patient’s survival time is approximately 44 ad-
ditional months. 
 The patients examined in this study were those ini-
tially registered to the German National Study for the 
Surveillance of TSE but after neuropathological workup 
finally diagnosed as having AD. We found this special 
group worthy of further detailed description, because it 
seemed to differ from classical AD populations regarding 
the multitude of focal signs. Since 1993 more than 2,800 
patients have been referred to the CJD Unit, one third of 
them suffered from clinically diagnosed AD  [8] . Roughly 
100–150 patients per year are diagnosed as having CJD, 
the sporadic form being predominant. Depending on the 
age group, 45–88% of them undergo autopsy  [8] . In a very 
small proportion, only AD pathology mostly without any 
other significant neuropathology was seen instead of 
CJD. The true proportion of rpAD considering all refer-
rals is not known due to the autopsy rate not being 100%.
 All cases studied here suffered from rapid cognitive 
decline and featured a short median survival time of 26.4 
months ( table 1 ). In these cases, the differential diagnoses 
typically comprise a variety of diseases such as inflam-
matory, paraneoplastic, metabolic or prion disorders  [8, 
11, 21–23] . The rapidity of the decline and the clinical fea-
tures may mislead the involved physician to suspect a pri-
on disease such as CJD as a typical representative of rap-
idly progressive dementias. AD itself is the most frequent 
differential diagnosis of CJD  [7–11] . It is important to 
mention that a clinical diagnosis of AD in this rpAD 
group is especially difficult as McKhann’s criteria for the 
diagnosis of AD (NINCDS-ARDRA) exclude focal neu-
rological signs, gait disturbances or impaired coordina-
tion in early stages  [24] . 
 Van Everbroeck et al.  [22] analogously published find-
ings on the clinical features of patients who were differ-
entially diagnosed as having another dementia than CJD 
out of an initially CJD suspect population from Belgium. 
Their mean patients’ age was 71 years at clinical onset, 
which is similar compared to this study. In both studies 
they were older than typical CJD patients. Regarding the 
clinical symptoms, we tried to differentiate more clinical 
signs and examine the time point of occurrence as well as 
analyze whether a symptom is an early-, middle- or late-
stage symptom. 
 The CSF parameters determined (tau,   -amyloid 
1–42;  table 1 ) were at similar levels to those in the study 
of van Everbroeck et al.  [22] . Mean CSF tau values of 803 
 8 553 pg/ml and mean   -amyloid 1–42 values of 265  8 
156 pg/ml for ‘typical’ AD patients have been previously 
reported in the literature  [25] . Cutoff values with good 
diagnostic sensitivity, specificity and predictive values 
have been suggested with total tau = 530 pg/ml and   -
amyloid 1–42 = 400 pg/ml  [26] . Considering those values, 
it is intriguing that, while   -amyloid 1–42 values were 
decreased as expected and as reported for slowly progres-
sive AD, the median tau values of our study group ap-
peared not to be elevated. Tau was even slightly decreased 
compared to patients whom van Everbroeck et al.  [22] 
differentially diagnosed as having AD out of a group ini-
tially suspected to suffer from CJD. Gloeckner et al. [27] 
show that tau is a good marker differentiating AD from 
CJD. The presence of 14-3-3 proteins in the CSF, which 
are a marker for neuronal destruction  [28] , was different 
from the study of van Everbroeck et al.  [22] . They found 
4% to be positive whereas 31% of the patients were tested 
positive in this study ( table 1 ). The detectability of 14-3-3 
proteins in rpAD has been previously reported for 1 case 
 [29] . This has important implications for TSE surveil-
lance units and their interpretation of this biomarker. 
The 14-3-3 proteins are a substantial marker in the dif-
ferential diagnostics of rapidly progressive dementia and 
prion diseases. Until now it has been supposed to be high-
ly suggestive of prion disease if inflammation, ischemia, 
hemorrhage and epileptic seizures have been excluded.
 Recent data point towards a possible link between the 
 PRNP -gene-encoded prion protein and AD as the prion 
protein PRPc might be involved in the regulation of the 
  -secretase-mediated cleavage of amyloid precursor pro-
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tein  [30] . Single-nucleotide polymorphisms within the 
 PRNP gene have been found that might be associated 
with AD  [31] . In that context the distribution of  PRNP 
gene polymorphism at codon 129 is fascinating. In our 
study 57% of the patients were found to be homozygous 
for methionine, while Riemenschneider et al.  [32] , who 
evaluated a ‘typical’ AD population and healthy controls, 
found 48% of the average AD population to be homozy-
gous for methionine and only 40% of the healthy popula-
tion. Some reports have demonstrated contradicting re-
sults on  PRNP codon 129 polymorphism in various neu-
rodegenerative conditions. Especially the influence on 
AD susceptibility, time of onset or patients’ rate of decline 
was examined. The study of Poleggi et al.  [33] does not 
support a role for  PRNP gene polymorphism as a suscep-
tibility factor for AD. Riemenschneider et al.  [32] and Li 
et al.  [34] draw a similar conclusion. In contrast, Del Bo 
et al.  [35] found methionine homozygosity or the methio-
nine allele at all to be a risk factor for AD as well as a cor-
relation between the rate of cognitive decline and valine 
homozygosity. 
 The ApoE type 4 allele is a well-known and accepted 
risk factor for AD  [1, 36, 37] . Contradicting data on the 
influence of ApoE type on disease progression rate are 
available in the literature. Martins et al.  [16]  demonstrate 
an influence, while Bracco et al.  [14] or Kleiman et al.  [15] 
rather disagree. Analysis of the ApoE type distribution in 
our study yields interesting results as well. We surpris-
ingly found no patient to be homozygous for ApoE4. 
Only 38% possessed at least 1 ApoE4 allele compared to 
approximately 59% of a typical AD population examined 
by Farrer et al.  [37] ( fig. 2 ). Our findings are partially con-
sistent with those of Giannattasio et al.  [38] who claim 
that absence of the type 4 allele might be a predictor of 
short survival in some AD patients.
 As a main objective of this study, we examined the 
clinical features in terms of symptom frequency, time 
span until onset and time point of onset relative to disease 
duration ( fig. 3 ). The development of clinical signs in de-
pendence on  PRNP gene codon 129 polymorphism was 
evaluated as well.
 Most of the patients experienced psychiatric symp-
toms apart from dementia ( fig. 3 ). Regarding the psychi-
atric symptoms evaluated, interestingly, visual or acous-
tic hallucinations as well as anxiety were far less frequent 
in methionine-homozygous patients than in heterozy-
gous ones. That difference is statistically significant (p = 
0.03).
 Motor signs and their frequency in AD patients have 
been described before  [39–42] . Scarmeas et al.  [41] report 
the frequency of motor signs in AD patients to increase 
during the course of the disease. Overall they showed 
tremor to be present in 11% of their AD population (38% 
in our study), rigidity in 26% (50% in our study) and pos-
ture instability/gait disturbance/falls in 29% (in our study: 
gait disturbance 66%, falls 50%). Motor signs also seem to 
be predictive of a poor outcome in AD  [13] . The observed 
high frequency of motor signs in the examined population 
with rpAD compared to the typical AD population as de-
scribed by Scarmeas et al.  [41] would be consistent with the 
reported prognostic capability regarding a poor outcome. 
 Grubenbecher et al.  [43] investigated the  PRNP codon 
129 polymorphism in Wilson’s disease and revealed M/M 
status appearing to be a risk factor for severer neurologi-
cal symptoms, especially for developing tremor. For 
tremor in particular there seems to be no predominance 
in M/M AD patients in this study (M/M vs. non-M/M = 
33 vs. 40%). Interestingly we observed dysmetria to ap-
pear far less frequently in non-M/M individuals com-
pared to methionine-homozygous patients.
 Myoclonus and epileptic seizures are known to occur 
in a proportion of AD patients. Approximately three 
quarters of rpAD patients suffered from myoclonus 
( fig. 3 ). The large percentage may be one of the main rea-
sons – apart from the celerity of decline – for suspecting 
CJD in the first place. Seizures were reported in 25%. Vo-
licer et al. [44] report that 21% of the examined AD pa-
tients suffered from epileptic events. This finding was 
also associated with faster decline in language functions 
 [44] . Occurrence of seizures seems to be significantly de-
pendent on  PRNP status (M/M vs. non-M/M = 50 vs. 
10%, p = 0.03).
 Vegetative features analyzed were weight loss, sleep 
disorders, incontinence and hyperhidrosis ( fig.  3 ). As 
Johnson et al.  [45] suggest, accelerated weight loss might 
be an indicator of AD. Almost a third of the observed 
rpAD patients experienced weight loss which they or 
their relatives felt to be abnormal and therefore signifi-
cant. Sleep disturbances occurred in 41% of the rpAD 
patients. Plazzi et al.  [46] suggest that the  PRNP codon 
129 polymorphism might affect sleep also in healthy in-
dividuals. The fact that approximately 25% of the methi-
onine-homozygous patients versus 50% of the non-M/M 
patients in our study suffered from sleep disturbances 
might be another hint to support the hypothesis of Plazzi 
et al.  [46] . Incontinence and the other autonomous signs 
evaluated were not seen to differ notably in dependence 
from  PRNP codon 129 polymorphism. 
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 Conclusion 
 With this paper we gave a descriptive overview of a 
special subtype of AD which is characterized by a very 
rapid course, short survival and a variety of focal neuro-
logical signs. A possible selection bias in this study has to 
be considered. Only cases having been reported to the 
German TSE Surveillance Unit were subject to this study. 
Cases were reported when CJD was suspected clinically. 
Therefore it is imaginable that rpAD forms which are 
characterized by fewer neurological symptoms might ex-
ist but were possibly not detected by this study.
 The prevalence of such rapid AD forms with poor 
prognosis is not known. Thus, for the treating physician 
it is important to know that such a disease entity exists in 
order not to be misled in the diagnostic process and, in 
the worst case, to mistakenly suspect CJD with far-reach-
ing consequences for the patient and affiliated persons. 
Dubois et al.  [47] suggested modified diagnostic criteria 
derived from McKhann’s criteria putting emphasis on 
imaging and biomarkers. Both however also exclude ear-
ly neurological focal signs as it seems appropriate for 
most AD cases. It might be of help to mention such ab-
normal AD subtypes within potentially new criteria not 
strictly excluding early focal signs.
 This small study serves as a basis for an ongoing lon-
gitudinal prospective study striving to elicit factors deter-
mining the course and the symptomatic appearance of 
rpAD in order to aid the diagnostic process. Those factors 
should comprise conventional as well as novel biomark-
ers, genetic characteristics and morphological as well as 
metabolic features discovered by means of neuroimag-
ing. Another task being work in progress focuses on the 
clinical differences between rpAD and CJD to aid the dis-
crimination of both illnesses by means of clinical signs 
and laboratory tests. 
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